News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

California Stem Cell, Inc. Release: Cancer Immunotherapy Platform Targets Broad Range of Metastatic Cancers


7/31/2013 9:46:07 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (CSC) has announced the completion of an internal study demonstrating that the company’s proprietary immunotherapy manufacturing process can be applied to multiple cancer types. Originally developed for late stage metastatic melanoma, the platform tissue culture technology has also been shown to work with tumor tissues from hepatocellular carcinoma, ovarian cancer, glioblastoma multiforme, and other solid tumor cancers.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES